title: Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future.
authors.affiliation: Clinical Oncology Program, National Cancer Institute, Bethesda, MD.
authors.forename: R
authors.initials: R
authors.lastname: Yarchoan
authors.forename: J M
authors.initials: JM
authors.lastname: Pluda
authors.forename: C F
authors.initials: CF
authors.lastname: Perno
authors.forename: H
authors.initials: H
authors.lastname: Mitsuya
authors.forename: S
authors.initials: S
authors.lastname: Broder
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D000998:Antiviral Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016049:Didanosine / Q000627:therapeutic use; D004351:Drug Resistance; D006678:HIV / Q000187:drug effects / Q000502:physiology; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000209:etiology; D012190:Retroviridae / Q000187:drug effects*; D018894:Reverse Transcriptase Inhibitors; D006377:T-Lymphocytes, Helper-Inducer / Q000473:pathology; D014779:Virus Replication / Q000187:drug effects; D016047:Zalcitabine / Q000627:therapeutic use; D015215:Zidovudine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D016047:Zalcitabine; D016049:Didanosine